Tag: Vaccines

As of Nov. 10, 2024, 29.7 percent of nursing home residents had received a 2024 to 2025 COVID-19 vaccine

34.7 percent of adults reported having received influenza vaccine; 17.9 percent received COVID-19 vaccine

Seasonal maternal RSV vaccination may be cost-effective, as well as nirsevimab, particularly for those with higher risks

Maternal vaccination two to three or three to four weeks before delivery linked to lower cord:maternal transfer ratios versus at least five weeks

From 2022 to 2023, there was a 20 percent increase in estimated measles cases worldwide, from 8,645,000 to 10,341,000

Fourteen of 18 patients had neoantigen-specific T-cell responses; recurrence-free survival was 87.5 percent at 36 months

Primary composite reactogenicity outcome noninferior for those receiving both vaccines simultaneously

Respiratory syncytial virus vaccination effective for adults aged at least 60 years

Global coverage with first and third doses of DTPcv and measles-containing vaccine stagnated during 2022-2023

Coverage lower among health care personnel at nursing homes, while coverage for COVID-19 2023-24 vaccine was much lower